NPCR Education and Training Series (NETS) Module 3: Quality Control for Central Registries Part 1-Section C: Registry Data Quality Control Tools
|
|
|
- Maud Long
- 10 years ago
- Views:
Transcription
1 NPCR Education and Training Series (NETS) Module 3: Quality Control for Central Registries Part 1-Section C: Registry Data Quality Control Tools Prepared by Scientific Applications International Corporation (SAIC) CDC Contract Number Centers for Disease Control and Prevention National Program of Cancer Registries Atlanta, Georgia 1
2 Registry Data Quality Control Tools 2
3 3 Data Quality Toolbox Computer edit checks Data queries Visual editing Audits Reabstracting, recoding Reliability Other methods Duplicate coding and/or data entry Physician review Quality control staff in a central registry can use a wide variety of tools to monitor the completeness, accuracy, and timeliness of cancer data. A number of these tools were mentioned in the previous session. Each has value for specific types of registry data. This particular drawer of the proverbial data quality toolbox works with individual data items in individual records. Later, we ll talk about quality control measures for aggregate data and monitoring central registry data patterns. 3
4 Range Inter-field Inter-record Inter-database Computer Edit Checks May not be able to check for 4 Subtle inconsistencies Incomplete records Illogical information Computer edit checks are by far the most cost-effective way to monitor data quality. A well designed set of computer edits can accomplish in seconds what it would take a Quality Control (QC) staff member hours or even days to complete. By using computer edit checks, the central registry can clear many cases through baseline edits, freeing up the staff to take on the more complex, subtle, or sophisticated aspects of quality control. Computer edit checks are a type of acceptance sampling, the process of inspecting, accepting, or rejecting a batch of data. In industry, acceptance sampling is performed on as the name indicates a sample of the product. In cancer registries, computerized edit checks should be performed on 100% of the registry s cases. The four different types of computer edit checks have different purposes, and we ll discuss each in a moment. Computerized edit checks are as smart as the person who wrote them, but they cannot find every incongruity in data. (Items may pass edits if coded to unknown, if there are inconsistencies or illogical information that the computer has not been programmed to detect, or information is missing.) 4
5 5 EDITS Standardized edits Edit standards/criteria NPCR Percent passing single and inter-field edits: 97% at 12 months; 99% at 24 months SEER 100% expected to pass edits NAACCR Gold: 100% must pass edits NCDB Silver: 97% must pass edits 100% must pass NCDB edits set EDITS stands for Exchangeable-edits, Data-dictionary and Information Translation Standard. CDC s NPCR is responsible for the development and maintenance of the EDITS software. NPCR also funds and supports the development and maintenance of the EDITS Metafiles. The EDITS Software Project began in 1990 when registry software developers identified a need for standardized executable computer edits on registry data fields. EDITS is a set of software tools that can be used to improve data quality and standardize the way data items are checked for validity. The EDITS tools are available in a variety of applications both interactive and batch process. EDITS provides software to support three types of data activities, defining standards for data quality, standardizing data collection processes, and analyzing data quality. Each national organization or agency has created its own set of computerized edits to be run on data submissions and each one has its own standard for passing edits. 5
6 NPCR Edit Recommendations State-specific edits Provide to reporters and vendors Facility edits before submission Corrections Fewer errors Learning opportunity 6 NPCR strongly recommends that each state develop their own state-specific edits; provide the edits to reporters and registry software vendors; and require their use. Each facility in your state should be running edits that meets your state s criteria before submitting their data to the central registry. Editing data before submissions is beneficial to both the facilities and the central cancer registry. For the facility, corrections can be made in a timely manner with immediate feedback to the abstractor(s). It means fewer corrections at the central registry saving time (perhaps saving time for facilities in that they would not be receiving as many calls from the central registry). Edits are always a learning opportunity and editing data before submission provides that learning opportunity in a very timely manner. Now we will discuss the various types of edits. 6
7 Purpose Range Checks Restrict data to allowable codes Use Flag values out of range Flag alphabetic characters in a numeric field Flag blanks Example Laterality cannot be code 8 or [blank] 7 Range checks are single field edits. The purpose is to identify any field having a code other than those defined as acceptable for that field. Other names for range check are allowable code edit check and data format edit. For example, the laterality field is a single digit, so it has a capacity of 10 defined codes (0 9). However, the following six codes are the only acceptable codes for this field: 0, 1, 2, 3, 4, and 9. A range check for the laterality field would check for values of 5, 6, 7, and 8 as well as a letter, blank, or empty field. If any of these codes are found, the field fails the edit. Range checks can be fairly detailed, depending on the data field. Values that can be used in a date field is another example. A range check may allow numbers in month, in day, a four digit year, and smart enough to know there are only 28 days in month 02 except in leap years. The range check may also be constructed to allow values representing unknown, such as 99 as the month or day, or 9999 for year. For certain fields, other non-date values may be allowed in the field, such as 00/00/0000 for none or never, and 88/88/8888 for not applicable. However, a true date field should never contain alphabetic characters. Range checks usually cannot be overridden by setting a review flag in the software; they must be fixed. 7
8 Purpose 8 Inter-field Edit Checks Check for logic among data fields Use Eliminate illogical or contradicting data Examples Site-sex edit: a male patient cannot have cervical cancer Date of diagnosis must be after date of birth Summary stage must be in situ if behavior code is /2 Inter-field edit checks compare the values in two or more data fields for logic. Inter-field edits are performed on a single patient-tumor record. Most standard edits do not look at the content of text fields as part of the logic check. There are literally dozens of data combinations that have to make sense on an abstract. For example, treatment dates should logically be after the date of diagnosis. Certain types of cancer are not usually found in young patients (prostate cancer in a patient under age 40). Patients who have surgical resection (Surgery of Primary Site codes in the range) should be histologically confirmed. Of course there are rare exceptions to inter-field edit checks like these. The FORDS manual and the NPCR data fields include a series of override flags to indicate that some combination of data field values may not seem logical but have been checked out and are true. 8
9 Purpose 9 Inter-record Edit Checks Assure consistency between tumor records Use Compare the same field in different tumor records for agreement Examples Tumor record #1 and tumor record #2 with different primaries for the same patient cannot have the same sequence number Patient name and Social Security number must be the same for both tumors Inter-record edit checks compare data fields between tumor records for the same patient. These edit checks can run on tumor records from different facilities for a single primary in the same patient as part of the case consolidation process, or between tumor records of different primaries on the same patient in the registry database. The classic example of an inter-record edit check is that a patient cannot be reported as alive at last contact on one tumor record and deceased on another tumor record. Such a conflict must be resolved. Similarly, there should be no discrepancies for patient Social Security number, date of birth, sex, race, or other patient identifiers. 9
10 Purpose 10 Inter-database Edit Checks Verify validity of data items or supplement existing data from sources outside the registry Use Compare registry data fields with other available databases Example Update date of death from death certificate Update date last contact from insurance file Inter-database edit checks have several purposes. They are primarily used during data linkage with files outside the registry. An inter-database edit check can flag discrepant information and can even decide which information is better. For example, there may be a death certificate for a patient in the registry who is currently reported as alive. If all the patient identifiers match and the reported date of death is after the date of last contact on the registry file, the edit check can flag the case for updating. If the date of death is before the reported date of last contact, the edit check can flag the case for further investigation. Similarly, a death certificate may provide a specific race category for a patient whose registry record lists race as unknown. A great deal of judgment is required of the quality control person reviewing interdatabase edit checks. It may not be possible to know which of two or more discrepant facts about the patient is true without further investigation. 10
11 If an Edit Check Finds Something Error messages must be meaningful Warning Advisory message that there is a conflict or unlikely combination of items Allows an override Error Identifies illogical data or contradiction between fields Requires correction 11 When an edit check finds a discrepancy or invalid data in a record, action must be taken. The edit check may trigger a warning or advisory message that the combination of data items is unlikely, or it may trigger a message that the conflict must be resolved. Edit check warnings signal further investigation of the inconsistencies. A 36- year-old patient actually may have prostate cancer. If the information has been investigated and found to be unusual but true, an edit check warning allows the abstractor or quality control person to set an override flag. An error message indicates there is an impossible combination of data fields or that there is invalid data in one of the fields. Some registry software programs will identify the fields or even jump to the field(s) requiring review and updating. Error messages require correction before the case passes. Your software may not differentiate between warnings and errors and may label both simply errors. In that case, some errors will have overrides and others will not. 11
12 If an Edit Check Finds Something Feedback to the abstractor is CRUCIAL! 12 If the edit checks are run at the central registry, feedback to data collectors on the types and patterns of errors identified during quality control activities is CRUCIAL. The feedback is part of the data collector s continuing education and can prevent or at least reduce the occurrence of similar edit check issues in the future. The data collector/reporter will never know what needs to be corrected unless the central registry provides them with information about both the error and the correction. Yes, this does take some time and resources on the part of the central registry, but it is the give part of the give-and-take of data collection. The reporter may choose to correct the facility database to make it compatible with the central registry, but the main purpose is to educate the reporter. Feedback to the abstractor provides the central registry with an opportunity to interact with the data collectors and is an acknowledgement that their data is important to the central registry. 12
13 Data Queries Lists or cross tabulations Visual review Unusual data Blanks and unknowns Implausible data 13 Data queries are software programs that allow the user to look for specific features of cases in the database. Data queries can generate lists of cases by case identifier and data field as well as crosstabulations of data fields. Usually the list or cross-tab requires visual review by the quality control staff. Data queries allow for a closer look at items for which there may be no edit check, or for which human judgment is necessary. For example, it is very unusual for a tumor size to be more than 10 centimeters (code 100). A data query can search for cases where CS Tumor Size is greater than 100 and less than 990. A printout of cases can be generated for review. The reviewer can request a printout of cases with lists of primary site, case identifiers, tumor size, method of diagnosis, one or more text fields, and other data items that would be helpful in validating tumor size. In some cases, such as an ovarian carcinoma, the large tumor size may be correct. In other cases, numbers may be transposed and the data needs to be corrected. Visual review of a list can also show missing data and implausible data not found on computer edit checks. Some fields allow blanks, such as AJCC Stage Group. It s relatively easy to see a hole in a list where a data item is blank. The visual review will identify those cases for further investigation. A sorted list can also indicate the percentage of cases that pass computerized edits but are actually coded as unknown. Monitoring the frequency of unknown values is an important part of quality operations. Data queries can be very creative. A query may be triggered by a news event or a question from a researcher. The point is that data queries offer the flexibility of searching the database for combinations of data fields that may pass edits, but may not make sense. If inconsistencies are found that cannot be verified with text information from the abstract, the items should be followed back to the submitting facility for review and comment. If corrections are made in the central registry database, the submitting facility should be notified of the change so that its database can be corrected as well. [Stress this point as part of central registry communication with its reporters!] NAACCR has developed a series of quality assessments that can be performed on any central registry database ( These assessments look for excess use of override flags and inconsistent coding. Data queries can be structured and saved, or ad hoc. In a central registry quality assurance program, there should be scheduling AND documentation of periodic review of the database using data queries. 13
14 Visual Editing Percent of cases visually edited Onscreen review Printed abstracts Logical consistency Related items Requires skilled quality control staff 14 Visual editing is the process of manually reviewing data fields on an abstract for consistency and logic. Visual editing can compare coded data fields to supporting text documentation, something that computer edit checks cannot do well. Visual editing validates the quality of abstracted data by comparing text and codes. Visual editing standards vary from state to state. Some registries perform 100% visual review of abstracts, others review a smaller percentage of cases, based on budget, availability of quality control staff, and other factors. The percentage of abstracts reviewed might even vary for new registrars versus experienced registrars. Some central registry software systems have built-in visual review mechanisms where data fields can be reviewed side-by-side for consistency. Others prefer printing out the abstract and reviewing the paper document. Visual editing looks for logical consistency among data fields and verifies that consistency by reviewing the supporting documentation. The importance of the supporting documentation cannot be emphasized enough, as it is what permits the record to be edited without going back to the source documents for confirmation. Examples of related items will be shown in a moment. It almost goes without saying that visual editing requires highly skilled quality control staff. Most often, visual editors are experienced hospital registrars who have joined the central registry. A visual editor must know data field codes, coding rules, the relationships between data items, site-specific cancer disease processes, and expected types of treatment by stage. The work takes extreme concentration and a large dose of common sense, and the skills take years to develop. 14
15 Visual Editing Why bother? To document problem areas To quantify reliability of data To make the abstractor think about interrelationships of data fields 15 We know that there are specific data items that are critical for central registry use. Why can t the central registry just take the abstractor s word that the data are accurate? The main reason to edit the data is to quantify the accuracy for the sake of data users (researchers, health planners, and everyone else). In the process, problem areas can be identified and the central registry can address the issues through guidelines, rules, and various types of training. It never hurts to make sure that the data going into the system is as good as it possibly can be. 15
16 Importance of Text Text is necessary to Support codes Support unusual site/histology combinations Explain unusual entries Document additional information or questions resolved Support accuracy of data Avoid pulling records again 16 Visual editing is a way to cross-validate data because it is entered twice once as code and once as text. The job of the visual editor is to review the codes and compare the meaning of the code to the text or narrative that supports it. Many central registries do not emphasize the importance of abstractors submitting supporting text, but then they are at a disadvantage when it comes to quality-controlling the codes. Unusual combinations of site and histology or other fields look very odd to a researcher if there is no explanation or justification of the apparent discrepancy. In addition, text can document a subcategory of a code or a more specific fact that is represented by a nonspecific code. To say again something we have already mentioned, text will validate or prove the choice of the code, making it more accurate and reliable. And not inconsequentially, proactive documentation will save retrieving the medical record again if a code is questioned by the central registry or a researcher. 16
17 Triggering a Visual Review 100% standard Random cases Edit check issues Reporter experience Problem hospital Problem site, histology, or treatment Rule and guideline changes 17 Various factors may trigger a visual review. If the registry s standard is to review 100% of abstracts, then every case will be visually edited. If the registry standard is lower, a number of factors should be considered. The registry may adopt a policy of reviewing a statistically random sample of all cases, such as every fifth case (e.g., 20% of cases) added to the central registry database. Or, any case that fails one or more computerized edit check may be flagged for visual review. Alternatively, the registry may target certain types of cases to be reviewed. For example, the registry may review 100% of cases submitted by novice abstractors (those with less than one year of experience) and review only 10% of cases submitted by experienced abstractors who have a track record of submitting high quality data. Often the policy is to review all cases submitted by novice abstractors until several sequential batches are error free. In the case of experienced abstractors, periodic spot-checking or review of random cases could identify an increase in error rates that may trigger a more complete review. Here again, acceptance sampling and statistical process controls can be used to set the thresholds for further review. The registry may choose to review a higher percentage of cases from a hospital with staffing problems or a hospital that hires unsupervised contract abstractors. The registry may target problem cases based on previous audits, such as lung cancers or lymphomas, or patients who would be expected to have a particular type of treatment. Cases abstracted in the few months after a major rule change is implemented can also be the subject of visual review. How does the process of visual review work? Let s take a look. 17
18 Visual Editing Policies and Procedures Guidelines Promote consistency Quality Control Plan 18 The next few slides and the notes that go with each one include very extensive lists of items for review during the visual editing process. Please note that these slides and notes could be very useful in developing your procedures for visual editing and could easily be formatted into a guide or checklist for visual editors. Of course the value of established guidelines and procedures is consistency among the visual editing staff. These slides and the notes can also be used to create part of your quality control plan. 18
19 19 Visual Editing The Panoramic View Are there many blank spaces? Is code 9 (unknown) used frequently? Are there other numeric red flags (.8, 88, 8)? Are all dates in logical order? Are text fields significantly different from coded field translations? Is treatment appropriate for site and stage? Is there logical progression from stage at initial diagnosis to recurrence and recurrence sites? Does the abstract tell a complete story? The following considerations are based on visual review of a paper abstract. The same concepts would apply if visual review is conducted on a computer screen, but the number of fields will be more limited at each point due to the constraints of the computer screen. Before you begin looking at individual fields, take a look at the panoramic view. This is the initial impression of the case. Review these questions as you look at the case. Is there anything that raises a red flag? Codes 8 and 9 will pass edits, but are they a signal of incomplete data? Does the text say sarcoma and a transposed histology code is translated as carcinoma? Remember that this first review is general, the specifics will arrive in a minute. 19
20 20 Related Demographic Items Surname Spanish origin Race Surname Place of birth Area code County Date of birth Date of diagnosis Sex (code 2) Name Marital status (if required) Maiden name Spanish origin Sex (>2) Primary site Age Occupation Age Marital status (if required by state) Age Primary site and histology Address Place of diagnosis City County This is a partial list of related items that can be compared during a visual editing session. It just takes a split second to look at these, assuming that there is data in the fields. The demographic fields include the basic personal identification of the patient and critical information for incidence reporting. Individual items are important too, not just pairs to compare. For example: Are standardized abbreviations used in the address? Does the Social Security number show all 9 digits? Does it start with an 8 or a 9? Does the patient's name correspond to the coded ethnicity? Name lists are available for Hispanic and Asian surnames. Does race correspond to name and birthplace? Does race correspond to primary site? For example, darker pigmented populations rarely develop skin melanomas, and Chinese have higher rates of nasopharyngeal and primary liver cancer than the general population. Does the area code of the patient's phone number correspond to the county of residence? Think about first names: Kaposi's sarcoma in females is infrequent Breast cancer in males occurs in about 1 in 100 breast cancers Check that the date of birth and the date of diagnosis are not transposed or the same. If the same, make sure that the primary site and histology are appropriate to an infant and add a remark to verify patient is a newborn. If the patient is female and married, does the married name or maiden name correspond to the coded ethnicity? If sex is coded 3 or 4 (big red flag). Keep in mind that: Hermaphrodites usually develop genital cancers such as ovary or testis. Transsexuals are at risk for Kaposi's sarcoma and lymphomas. Monitor the age carefully. Any age 000 or 100 should be a red flag to be checked and verified. Any age < 30 or above 90 should be checked. A child (15 or under) would not normally have an occupation other than child or student. Also, check for a parent listed somewhere on the abstract. A child (15 18) would not normally be married, widowed, divorced, or separated. If married, document in remarks. A child would not normally have an epithelial cancer. Children develop leukemia, lymphoma, astrocytoma, neuroblastoma, sarcoma, hepatoblastoma, Wilms' tumor, or retinoblastoma. In contrast, nearly two-thirds of cancers cases occur in patients aged 65 years and older. Adults rarely develop retinoblastomas, Wilms' tumor, or bone tumors. Super-annuated (elderly) patients usually develop prostate, lung, breast, or colorectal cancer. Is there a difference between where the patient resides and where she or he was diagnosed or treated? This might be a signal that the patient has more information at a facility closer to home, or that the patient is a nonresident of the area. Is the city in the correct county? And by the way, is the ZIP Code numerically correct and within the range for your area? 20
21 21 Related Diagnosis Items Primary site code Text Histology code Text Site Laterality Histology Behavior Diagnostic confirmation Dx confirmation Histology > 8000 Are dates in logical sequence? Is Dx date the earliest documented? Class of case Facility referred to/from Dx date Place of diagnosis Site Type of admission Sequence no. Other primaries listed in text Diagnosis fields include some administrative fields and the majority of supporting text fields. Does the translation of the code say nearly the same thing as the text? Does the text justify the codes? Does the histology code translation say the same thing as the pathology text? Do the primary site and histology make sense together? Primary site is it documented in the text? Which text? Is the site code correct? Is the subsite specific or NOS? Is an NOS code validated? Is a.8 site code described in the text? What does the tumor overlap? Does the site and histology combination make sense? Some site-histology combinations intuitively go together, such as prostate with adenocarcinoma, head and neck with squamous cell carcinoma. Know too what site-histology combinations are unlikely, such as adenocarcinoma of the upper and middle esophagus, or carcinoma in the bone or spleen. Is this a paired site, and is the laterality documented in the text? Does behavior correspond to diagnostic confirmation? Is this an in situ case diagnosed clinically or by cytology? Or maybe a multiple myeloma diagnosed on electrophoresis. Is there a specific cell type coded if there is microscopic tissue confirmation? Does the differentiation code agree with the text, for example code 3 for moderately to poorly differentiated tumor? Are dates of diagnostic procedures before date of treatment? Are excision dates after needle biopsy dates? Is the diagnosis date the earliest date a recognized medical practitioner said the patient had cancer? Is that date between the admit and discharge dates? Date of diagnosis is it clear how and where the patient was diagnosed on this date? Do all of the dates lead up to the tissue diagnosis and definitive treatment? Do the first four digits of the accession number reflect the date of admission of the first primary cancer for this patient at the facility? If the patient is not a class of case 1, are hospital referred from and hospital referred to filled in as appropriate? (Referred from for class 2 and referred to for class 0.) Does the diagnosis date correlate to the place of diagnosis? Is the type of admission appropriate to the primary site? For example, is the patient having brain surgery as an outpatient? If the sequence number is greater than 00, are any other primaries documented in the remarks space? What about number of reportable by agreement cases and/or benign and borderline tumors collected by the registry? And by the way, if this case is sequence 02, does the previous abstract say sequence 01, rather than sequence 00? 21
22 22 Related Staging Items Stage Primary site CS codes Procedures text CS Extension Summary stage ct or pt CS Extension SSFs (by site) Age Pediatric stage CS Lymph Nodes cn or pn Summary stage CS Lymph Nodes SSFs (by site) Tumor size > 100 Nodes pos/exam Surgery CS Mets at Dx cm or pm Summary stage Staging basis Dates of treatment NPCR, SEER, COC, and NAACCR studies have shown that the staging fields are the most prone to problems, because coding these fields requires interpretation and sometimes the codes or the rules are rather subjective. However, these fields are vital for monitoring cancer trends and treatment. The elements of Collaborative Staging are for the most part facts, and they can be mapped to other stages. If the other staging fields are completed by physicians, this is another way of crosschecking the data. Does the stage correlate to the primary site? Do you have an in situ sarcoma? Do you have a regionalized leukemia? Do you have a localized unknown primary? How about a Stage IV melanoma? Are the CS codes supported by text? Are the CS codes correct for the time frame, according to the dates of various procedures? Does the T (clinical and/or pathologic) correspond to summary stage and is CS Extension in the range 00 80? It would be unusual to have a physicianstaged T1 and an Extension code of 50, or a summary stage localized with Extension in the range. If patient is a child, is a pediatric stage (rather than an AJCC stage) shown? Does the N (clinical and/or pathologic) correspond to summary stage regional to lymph nodes or regional nodes and extension, and is the CS lymph node code > 00 if N1? Is tumor size an important criterion for this site? If so, does it have a valid number? Is tumor size greater than 10 cm? And is size documented in text? Is clinical stage based on information before treatment was started? Is pathologic stage based on adequate surgical and pathological information? 22
23 23 Related Treatment Items Planned first course listed? Treatment Primary site Stage Treatment code Procedure name Treatment Facility referred from/to Surgery Operative findings text Surgery Pathology text Date 1 st surg Date most definitive surg Date most definitive surg Date surg discharge Surg prim site Margins Surg prim site Scope reg LN Surg prim site Reason no surg The treatment fields are where you need to widen your focus. From the codes and supporting text, can you tell what the planned first course of treatment was, and what the reasons were if the patient did not receive the usual treatment for the site and stage of disease? Do the treatment codes, particularly the surgery codes, include the procedure named in the text? Compare treatment fields and treatment this hospital fields. If they don t match, is a referral hospital documented? Is the surgical procedure listed in both the surgery code area and the operative findings? Here again, are the dates of treatment in logical order? If there was a big surgery to the primary site, were lymph nodes removed as well? Was there a pathology specimen? Is Dx confirmation appropriate to the surgery and path information? Does the pathology report correlate to which organs were removed in the coded and named surgery? 23
24 24 Related Treatment Items Surgery Radiation RT/surgery sequence Date RT start Date RT end Location of RT Facility referred from/to RT treatment volume Reason no RT RT treatment volume Boost treatment volume Systemic tx Primary site Systemic tx date Chemo Hormone Immunotherapy Systemic tx date Date most definitive surg Systemic/surg sequence Hemat Transpl & Endocr Proced Primary site RT treatment volume Palliative care Is the radiation modality code supported by text? Are drugs listed in text for chemo, hormone, and/or immunotherapy, and are they coded correctly? For example, is Levamisole coded as chemo rather than immunotherapy as it should be? Is Rituxan coded as immunotherapy rather than chemo as it should be? If systemic therapy changed, was there disease progression documented (the change would be coded in subsequent therapy, which may not be on the central registry abstract) or was the change planned as part of first course (CHOP-ABVD or induction and maintenance therapy for leukemia)? Does the primary site correlate to systemic treatment? Is there an early stage cancer receiving chemotherapy without evidence of involved nodes? Do the dates of treatment support the codes for surgery/rt sequence and surgery/systemic therapy sequence? If any type of treatment was refused, is the reason documented in text? Look at the radiation treatment fields if they look like sites that would receive palliative treatment, is the palliative care field also coded? 24
25 Resolving Visual Review Discrepancies Automatic correction rules Specific codes replace unknowns or blanks Notification of data changes to facility Follow-back to data collector To resolve conflicting information Discrepancy reports 25 When better information can be identified from the text, specific codes replace unknowns or blanks on the abstract. The central registry may also have other automatic correction rules. Once again, it is crucial that any discrepancies identified in visual review be reported back to the facility as part of an ongoing quality improvement process for the reporter. Queries back to the data collector should be used to resolve conflicting information as well as provide periodic discrepancy reports. 25
26 26 California Cancer Registry Visual Review Procedures 130,000+ cases annually Visually edit 100% of cases 97% accuracy rate Accuracy rate reported to hospital administrator For 2008, 32 fields will be reviewed Demographics (8) Diagnosis (12) including new MP/H fields Staging (12) Visual editing is not a new concept. For example, until recently the California Cancer Registry has been visually editing 100% of its new cases, with more than 130,000 new incident cases added to the state database every year. That s a lot of visual editing. In 2000, the California Cancer Registry and its 10 regions implemented the most stringent quality control standards in the world. The state established a 97% accuracy rate for 13 data items that would be visually edited by the regional registry. The accuracy rate would be reported to the facility s administrators on a periodic basis. Since 2000, the number of data fields as been expanded, and in 2008, 40% of the data will have 32 fields visually edited with that same expected 97% accuracy rate. This standard of accuracy places a tremendous responsibility on the data collector and as much a burden on the visual editors, but the results have proven worth the effort. As of the first quarter, 2007, the AVERAGE accuracy rate for all hospitals is 98.6%! 26
27 California Visual Editing 2008 Fields Edited (simplified) (1) County of Residence at Dx Sex Race Fields Spanish/Hispanic Origin Date of Diagnosis Date of Conclusive Dx Class of Case Diagnostic Confirmation Ambiguous Terminology Dx Site/Subsite Grade Multiple Tumors Reported as One Primary Date of Multiple Tumors Multiplicity Counter CS Tumor Size CS Extension CS Lymph Nodes Number Regional Nodes Positive/Examined CS Mets at Diagnosis Laterality (only paired sites listed) Histology Type Site-specific Factors These are the demographic, diagnostic, and staging fields that are visually reviewed in 2008 in California. Note that they include the fields added to document the multiple primaries and histology coding rules that were implemented in Note also that text fields are not included in this list but are required to support the coded fields listed. 27
28 Date of Surgery Surgery of the Primary Site At This Hospital Scope of Regional LN Surgery At This Hospital Surgery of Other Reg/ Distant Sites This Hosp Radiation Reg Treatment Modality (Summary) Radiation Reg Boost Modality (Summary) Date of Chemotherapy Chemotherapy (Summary) 28 Visual Editing Treatment Fields Hormone Therapy Date Hormone Tx (Summary) Immunotherapy Date Immunotherapy (Summary) Transpl and Endocr Proced Date Transpl and Endocr Proced (Summary) Other Therapy Date Other Therapy (Summary) The treatment fields on this slide can be added to the list of data items for visual review. Again, note that text fields are not included in this list but are required to support the coded fields listed. If your central registry has never done visual editing, or if you are just starting this quality improvement technique, start with just a few visual edits, particularly those that affect incidence reporting. Or, pick 10 or 12 data items that are used most frequently in research in your state. As the visual editing process matures, you can expand the number of fields that come under scrutiny as staffing and resources permit. 28
29 Other Data Quality Control Methods Physician review Audits 29 Other than computer edit checks and visual editing, there are other data quality control methods or tools that can be used. Physician review of cases is a requirement in Commission on Cancer approved facilities. At the central registry level it is more of a luxury and should be reserved for difficult, complex, or medically challenging cases. Any consultation with a physician advisor should be documented on the case at the central registry level. Audits perform a vital role in quality control of registry data. Audits and designed studies can identify trends and gaps in training, but generally do not have an immediate direct effect on data quality. It is only over time after the problems have been identified and training has been done that audits can affect the data. Audits will be covered in later sessions. 29
30 When abstracting Common Sense When editing 30 In medicine, the Zebra Rule is "When you hear hoofbeats, think of horses, not zebras. Although physicians are trained to identify exotic and unusual diseases, they are also frequently reminded that most diseases are the common types. In a cancer registry, that rule has two aspects. When you are abstracting, think horses. When you are editing, think zebras. In other words, when you are abstracting, think of common things that you would expect to be found. When you are editing, look for the unusual things that don t make sense or stand out from the usual. 30
31 Central Registry Data Patterns Incidence rates Age distribution Percent microscopically confirmed Race distributions by site Trends in Top 5 or Top 10 sites 31 In central cancer registries data patterns that should be analyzed to ascertain if they meet expected norms. Common sense and comparison to other central registries should be the bases for this type of quality review. The following examples show common sense observations and rules of thumb. Incidence rates and frequencies should be greater than mortality rates and frequencies. If mortality rates appear to be greater, this MUST be verified. Where the age distribution of the population at risk is similar to the national norm, childhood cancers should represent about 1% of the total number of cases. Cancers in persons over 80 years of age should account for approximately 15% of the total. In the U.S. the microscopically confirmed cases should represent approximately 93%. This will vary by state and even within states according to distance to a treating facility and other measures of access to medical care, such as socioeconomic criteria. However, every central registry should have a mix of pathologically and clinically diagnosed cases. Certain race distributions should be observed by site. Examples identified over years of analysis include Rates for cancer of the corpus uteri should be higher for whites than for blacks, and rates for cervix uteri should be higher for blacks than for whites. Significant numbers of melanomas occur only in the white population. Cancer of the prostate should be higher for blacks. Rates for Hispanics are generally lower than for whites except for cervix uteri, esophagus, stomach, and pancreas. Certain site-specific patterns should be observed. Examples include Death certificate only cases for lung, liver, and pancreas. Unknown primary site should be about 5% of all cases. Male breast cancer usually accounts for about 1/2% to 1% of all breast cancer cases. Trends in the top 5 or top 10 sites by sex will fluctuate slightly, but generally will include Breast, lung, colorectal, corpus uteri, lymphoma, and/or ovary for women. Prostate, lung, colorectal, bladder, melanoma, and/or lymphoma for men. Trends in the top 5 or top 10 sites by race or ethnicity will also fluctuate, but generally will include Breast, lung, colorectal, corpus uteri, cervix, and/or thyroid for Hispanic women. Breast, lung, colorectal, corpus uteri, lymphoma, and/or pancreas for African American women. Prostate, colorectal, lung, lymphoma, kidney/renal pelvis, and/or bladder for Hispanic men. Prostate, colorectal, lung, lymphoma, kidney, and/or oral cavity for African American men. 31
32 Site-specific Data Patterns Percent unknown primary Percent Death Certificate Only NPCR SEER 3% at 24 months 1.5% at 22 months NAACCR Gold: 3% Silver: 5% Demographic distribution Age distribution 32 NPCR, SEER, and NAACCR have set standards and criteria for the maximum percentage of cancers of unknown origin and death certificate only. These percentages affect the overall frequency distribution of the state s annual incidence rates. In addition to these general patterns, site-specific data patterns need monitoring. It is extremely important that the central registry obtain accurate census information on the population within its geographic area, because the race distribution of the population will affect both the incidence counts and the incidence rates for the geographic area in general. Understanding the race and ethnicity distributions in the population will help make sure that there are no anomalies in cancer registry aggregate data. Similarly, understanding the age distribution within the state s population will help account for any variability in cancer incidence when the state s data is compared to national data or to other states. 32
33 Data Usage Review of data prior to release for research project Data review prior to publication Coding changes over time Registry procedures Casefinding completeness Follow-up rate Percent unknowns 33 Finally, independent eyes looking at the data those of researchers using the data can find inconsistencies and issues in both individual and aggregate data that may not be seen when individual abstracts are processed through quality control methods. Obviously, if the researchers identify significant issues, the overall quality of the data becomes a cause for concern, but the feedback from researchers on incongruities in the data (in contrast to true errors) can only strengthen the application of computer edits and visual editing procedures. When the data are requested by a researcher, it is a good idea for the registry to review the data for discrepancies prior to releasing it. At this point, corrections in the data only make it better for research. When the research is about to be published, the registry staff should request to review the data once more, to assure that the researchers have not come to invalid conclusions based on data problems. In addition to the data itself, the registry should provide any researcher with information pertinent to the data. This includes Coding changes over time there may have been some stage migration due to advances in medical diagnostics, new morphology codes, or different ways of coding treatment over the period for which the data were requested. Estimates of casefinding completeness. As previously noted, incomplete casefinding can skew the findings in some primary sites. If the registry includes follow-up data, information on the successful follow-up rates by patient age should be provided to the researchers, particularly if they are analyzing survival trends or other outcomes measures. Percent unknowns by data field here again, a large percentage of unknown values in a critical data field can confound the researcher s findings. The researcher and the registry must work together to determine ways to counteract a high percentage of unknowns. (Go to Module 3, Part I Section D.) 33
34 The findings and conclusions in this presentation are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Note: Some images in this presentation 2008 Jupiterimages Corporation. Used with permission. 34
35 For information about CDC s Cancer Prevention and Control Programs and the National Program of Cancer Registries Please visit npcr 35 35
General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
The Ontario Cancer Registry moves to the 21 st Century
The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer
Number. Source: Vital Records, M CDPH
Epidemiology of Cancer in Department of Public Health Revised April 212 Introduction The general public is very concerned about cancer in the community. Many residents believe that cancer rates are high
NPCR Education and Training Series (NETS) Module 3: Quality Control for Central Registries Part 1-Section A: General Overview
NPCR Education and Training Series (NETS) Module 3: Quality Control for Central Registries Part 1-Section A: General Overview Prepared by Scientific Applications International Corporation (SAIC) CDC Contract
Investigating Community Cancer Concerns--Deer Park Community Advisory Council, 2008
Investigating Community Cancer Concerns--Deer Park Community Advisory Council, 2008 David R. Risser, M.P.H., Ph.D. [email protected] Epidemiologist Cancer Epidemiology and Surveillance Branch
Chapter 13. The hospital-based cancer registry
Chapter 13. The hospital-based cancer registry J.L. Young California Tumor Registry, 1812 14th Street, Suite 200, Sacramento, CA 95814, USA Introduction The purposes of a hospital-based cancer registry
Chapter I Overview Chapter Contents
Chapter I Overview Chapter Contents Table Number Contents I-1 Estimated New Cancer Cases and Deaths for 2005 I-2 53-Year Trends in US Cancer Death Rates I-3 Summary of Changes in Cancer Incidence and Mortality
C a nc e r C e nter. Annual Registry Report
C a nc e r C e nter Annual Registry Report 214 214 Cancer Registry Report Larraine A. Tooker, CTR Please note that the 214 Cancer Registry Annual Report is created in 214, but it reflects data on cases
Ovarian Cancer. in Georgia, 1999-2003. Georgia Department of Human Resources Division of Public Health
Ovarian Cancer in Georgia, 1999-23 Georgia Department of Human Resources Division of Public Health Acknowledgments Georgia Department of Human Resources......B. J. Walker, Commissioner Division of Public
Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013. National Registry of Diseases Office (NRDO)
Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013 National Registry of Diseases Office (NRDO) Released November 3, 2014 Acknowledgement This report was
Cancer in Ireland 2013: Annual report of the National Cancer Registry
Cancer in 2013: Annual report of the National Cancer Registry ABBREVIATIONS Acronyms 95% CI 95% confidence interval APC Annual percentage change ASR Age standardised rate (European standard population)
The Ontario Cancer Registry and its Data Quality. Diane Nishri Senior Research Associate, Surveillance February, 2011
The Ontario Cancer Registry and its Data Quality Diane Nishri Senior Research Associate, Surveillance February, 2011 Objectives Become familiar with cancer registration in Ontario, including issues related
DELRAY MEDICAL CENTER. Cancer Program Annual Report
DELRAY MEDICAL CENTER Cancer Program Annual Report Cancer Statistical Data From 2010 TABLE OF CONTENTS Chairman s Report....3 Tumor Registry Statistical Report Summary...4-11 Lung Study.12-17 Definitions
CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
How To Know If You Have Cancer At Mercy Regional Medical Center
MERCY REGIONAL CANCER CENTER 2012 CANCER PROGRAM ANNUAL REPORT Using 2011 Data Mercy Regional Cancer Center When you have cancer, you might think first of treatments chemotherapy and radiation. You want
chapter 5. Quality control at the population-based cancer registry
chapter 5. Quality control at the population-based cancer registry All cancer registries should be able to give some objective indication of the quality of the data that they have collected. The methods
Treatment Part Two 1 FLORIDA CANCER DATA SYSTEM Treatment - Part Two
Treatment Part Two 1 Prerequisites 2 Completion of FCDS, Introduction to Abstracting module Completion of FCDS, Treatment Part One Learning Objectives 3 Recognize cancer treatment modalities Acquire a
GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.
GENERAL CODING When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. Exception: You must review and revise EOD coding for prostate
FCDS 2013-2014 QUALITY IMPROVEMENT EDUCATION AND TRAINING
FCDS 2013-2014 QUALITY IMPROVEMENT EDUCATION AND TRAINING FCDS Webcast Series Steven Peace, BS, CTR Mayra Espino, BA, RHIT, CTR October 24, 2013 2 Continuing Education Hours NCRA CEU # Date Event Sponsor
ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival
ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival It is logical that the Cancer Program Committee choose to review the Lung Site, as Lung is the second
Lung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
Section 8» Incidence, Mortality, Survival and Prevalence
Section 8» Incidence, Mortality, Survival and Prevalence 8.1. Description of Statistics Reported This section focuses on the regional distribution of cancer with data derived from the BC Cancer Registry
Effective For Cases Diagnosed January 1, 2015 and Later
POLICY AND PROCEDURE MANUAL FOR REPORTING FACILITIES May 2015 Effective For Cases Diagnosed January 1, 2015 and Later Indiana State Cancer Registry Indiana State Department of Health 2 North Meridian Street,
Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules KIDNEY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
PROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
Bristol Hospital Cancer Care Center 2015 Annual Report
Bristol Hospital Cancer Care Center 2015 Annual Report 2015 Annual Report Cancer Care Center At every point along the path, our team is there, keeping the focus on the most important team member - the
THE CANCER CENTER 2013 ANNUAL REPORT CONTAINING 2012 STATISTICS
THE CANCER CENTER 2013 ANNUAL REPORT CONTAINING 2012 STATISTICS Northside Medical Center Cancer Committee Mission Statement It is the mission of the Cancer Committee to evaluate and monitor the care of
Cancer Screening and Early Detection Guidelines
Cancer Screening and Early Detection Guidelines Guillermo Tortolero Luna, MD, PhD Director Cancer Control and Population Sciences Program University of Puerto Rico Comprehensive Cancer Center ASPPR Clinical
National Cancer Institute
National Cancer Institute Information Systems, Technology, and Dissemination in the SEER Program U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Information Systems, Technology,
Cancer Survival in New Jersey 1979-2005
Cancer Survival in New Jersey 1979-2005 Cancer Epidemiology Services Public Health Services Branch New Jersey Department of Health Chris Chris e, Governor Kim Guadagno, Lt. Governor Mary E. O Dowd, MPH
New Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
The Burden of Cancer in Asia
P F I Z E R F A C T S The Burden of Cancer in Asia Medical Division PG283663 2008 Pfizer Inc. All rights reserved. Printed in USA/December 2008 In 2002, 4.2 million new cancer cases 39% of new cases worldwide
Conversion to NAACCR 13
OCCR Oklahoma State Department of Health Oklahoma Central Cancer Registry NewsFlash January 2013 Winter Issue I NSIDE T HIS I SSUE 1 New OK CTRs 1 New OCCR Staff 2 Conversion to NAACCR 13 3 New Requirement
Statistics fact sheet
Statistics fact sheet Fact sheet last updated January 2015 EXTERNAL VERSION Macmillan Cancer Support Page 1 of 10 Macmillan and statistics Statistics are important to Macmillan because they help us represent
Chapter 6 Case Ascertainment Methods
Chapter 6 Case Ascertainment Methods Table of Contents 6.1 Introduction...6-1 6.2 Terminology...6-2 6.3 General Surveillance Development...6-4 6.3.1 Plan and Document... 6-4 6.3.2 Identify Data Sources...
Pediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006
Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator November 2015 334 Jefferson Avenue, Scranton,
The Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
Hospital-Based Tumor Registry. Srinagarind Hospital, Khon Kaen University
Hospital-Based Tumor Registry Srinagarind Hospital, Khon Kaen University Statistical Report 2012 Cancer Unit, Faculty of Medicine Khon Kaen University Khon Kaen, Thailand Tel & Fax:+66(43)-202485 E-mail:
Chapter 21: Managing Abstracting Assignments
Chapter 21: Managing Abstracting Assignments Casefinding or abstracting assignments are maintained and tracked in SEER*DMS as Abstract Facility Leads (AFLs). As a record or patient set is processed, an
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
Early Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
An Introduction to the. cancer registry. instructor s guide
An Introduction to the cancer registry instructor s guide National Cancer Registrars Association Education Foundation 1340 Braddock Place, Suite 203 Alexandria, Virginia 22314 (703) 299-6640 www.ncraeducationfoundation.org
Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.
Underwriting cancer In this issue of the Decision, we provide an overview of Canadian cancer statistics and the information we use to make an underwriting decision. The next few issues will deal with specific
Chapter 16: Follow-up
Chapter 16: Follow-up The term follow-up refers to the process whereby a registry continues to monitor the status of a patient's health at periodic intervals. Data fields concerning patient vital status,
Death Data: CDC Wonder, Texas Health Data, and VitalWeb
Death Data: CDC Wonder, Texas Health Data, and VitalWeb Evidence-Based Public Health Practice Step 2: Quantify the Issue This handout demonstrates how to access CDC Wonder, Texas Health Data, and VitalWeb
Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
NCI Community Cancer Centers Program Program Overview Ascension Health St. Vincent Indianapolis Hospital
A. Name and location of hospital:, Indianapolis, IN B. Name of cancer center: St. Vincent Oncology Center C. Identify PI and key personnel with contact information for each pilot focus areas: a. Disparities
Table 2.2. Cohort studies of consumption of alcoholic beverages and cancer in special populations
North America Canada Canadian 1951 Schmidt & Popham (1981) 1951 70 9 889 alcoholic men, aged 15 years, admitted to the clinical service of the Addiction Research Foundation of Ontario between Death records
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
R E X C A N C E R C E N T E R. Annual Report 2012. Rex Cancer Care Committee 2012 On behalf of the Rex Cancer Center & Rex Health Care
R E X C A N C E R C E N T E R Annual Report 2012 Rex Cancer Care Committee 2012 On behalf of the Rex Cancer Center & Rex Health Care An American College of Surgeons Commission on Cancer Accredited Comprehensive
The effect of the introduction of ICD-10 on cancer mortality trends in England and Wales
The effect of the introduction of ICD-10 on cancer mortality trends in Anita Brock, Clare Griffiths and Cleo Rooney, Offi ce for INTRODUCTION From January 2001 deaths in have been coded to the Tenth Revision
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:
Cancer Facts & Figures for African Americans 2013-2014
Cancer Facts & Figures for African Americans 213-214 Contents Cancer Statistics 1 Selected Cancers 1 Cancer Prevention & Early Detection 14 Screening Guidelines for the Early Detection of Cancer in Average-risk
Directly Coded Summary Stage Is Back
Directly Coded Summary Stage Is Back Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry June 30, 2015 1 Outline What is SEER Summary Stage 2000 (SS2000)? Summary Stage Housekeeping
4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma
Chapter Sixteen Oncology bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o Combining Forms Prefixes and Suffixes Carcinogenesis anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Causes of cancer
Oncology Medical Home Measure Specification Data
Oncology Medical Home Measure Specification Data Measure Name Chemotherapy pathway compliance Measure # 1 Measure Description % of chemotherapy treatments that have adhered to NCCN guidelines or pathways.
Total Cost of Cancer Care by Site of Service: Physician Office vs Outpatient Hospital
Total Cost of Cancer Care by Site of Service: Physician Office vs Outpatient Hospital Prepared by Avalere Health, LLC Page 2 Executive Summary Avalere Health analyzed three years of commercial health plan
Frequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 [email protected] Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
Abstract Code Manual
13th Edition Abstract Code Manual MISSOURI CANCER REGISTRY AND RESEARCH CENTER University of Missouri Columbia 2013 Revised Missouri Cancer Registry and Research Center Abstract Code Manual 13th Edition
Abstracting and Coding Manual For Hospitals
DATA COLLECTION MANUAL MASSACHUSETTS CANCER REGISTRY Abstracting and Coding Manual For Hospitals Fifth Edition December 2003 includes revisions through July 2007 corresponding to NAACCR Data Exchange Record
The Cancer Center of Chester County Annual Report 2006 With statistical data from 2005
06 The Cancer Center of Chester County Annual Report 2006 With statistical data from 2005 2005 Statistical Report Community Screenings Screening Participants Normal Results Referred for Follow-up Colon
Chapter 2 History of MD Anderson s Tumor Registry
Chapter 2 History of MD Anderson s Tumor Registry Sarah H. Taylor The Tumor Registry Department at The University of Texas MD Anderson Cancer Center is responsible for a database that contains demographic
Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
Butler Memorial Hospital Community Health Needs Assessment 2013
Butler Memorial Hospital Community Health Needs Assessment 2013 Butler County best represents the community that Butler Memorial Hospital serves. Butler Memorial Hospital (BMH) has conducted community
Collaborative Stage Data Collection System Version 2: 0204. Implementation Guide for Registries and Vendors
Collaborative Stage Data Collection System Version 2: 0204 Implementation Guide for Registries and Vendors Elaine N. Collins Minnesota Cancer Surveillance System December 5, 2011 Implementation Issues
Chapter 14 Cancer of the Cervix Uteri
Carol L. Kosary Introduction Despite the existence of effective screening through the use of Pap smears since the 195 s, there were 9,71 estimated cases of invasive cervical cancer and 3,7 deaths in 26
NEOPLASMS C00 D49. Presented by Jan Halloran CCS
NEOPLASMS C00 D49 Presented by Jan Halloran CCS 1 INTRODUCTION A neoplasm is a new or abnormal growth. In the ICD-10-CM classification system, neoplastic disease is classified in categories C00 through
Health Care Access to Vulnerable Populations
Health Care Access to Vulnerable Populations Closing the Gap: Reducing Racial and Ethnic Disparities in Florida Rosebud L. Foster, ED.D. Access to Health Care The timely use of personal health services
2012 Oncology Service Line Goals and Accomplishments
2012 Oncology Service Line Goals and Accomplishments 2012 Program goals and outcomes Quality and Service Seek NAPBC accreditation by December 31, 2012 Application was accepted; visit date set for April
Tricia Cox on 7/18/2012 at Oncology Center. Sarah Randolf. Female
SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,
Aggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
AG CancerCare Platinum Plus Initial Diagnosis Benefit First occurrence Internal cancer only (one-time payment)
AG CancerCare from American General Life Insurance Company (American General Life) is a specified disease policy that pays benefits for expenses related to the diagnosis and treatment of cancer, as well
www.e-mercy.com Mercy Health Fairfield Hospital Annual Report on 2010 Activities Non-Hodgkin Lymphoma Outcomes Study
www.e-mercy.com Mercy Health Fairfield Hospital Annual Report on 2010 Activities Non-Hodgkin Lymphoma Outcomes Study Cancer Program Summary The Cancer Program at Mercy Health - Fairfield Hospital has maintained
